Cargando…

Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment

The angiogenesis inhibitor ramucirumab (IMC-1121B) is a fully humanised IgG1 monoclonal antibody targeting the extracellular domain of vascular endothelial growth factor receptor 2. Ramucirumab has been approved as a second-line treatment for lung cancer. Pyogenic granuloma is an acquired, benign va...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibe, Tatsuya, Hamamoto, Yoichiro, Takabatake, Mikage, Kamoshida, Shingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887457/
https://www.ncbi.nlm.nih.gov/pubmed/31776151
http://dx.doi.org/10.1136/bcr-2019-231464
_version_ 1783475034894893056
author Ibe, Tatsuya
Hamamoto, Yoichiro
Takabatake, Mikage
Kamoshida, Shingo
author_facet Ibe, Tatsuya
Hamamoto, Yoichiro
Takabatake, Mikage
Kamoshida, Shingo
author_sort Ibe, Tatsuya
collection PubMed
description The angiogenesis inhibitor ramucirumab (IMC-1121B) is a fully humanised IgG1 monoclonal antibody targeting the extracellular domain of vascular endothelial growth factor receptor 2. Ramucirumab has been approved as a second-line treatment for lung cancer. Pyogenic granuloma is an acquired, benign vascular tumour of the skin or mucous membrane. We encountered a patient with pyogenic granuloma who was treated with ramucirumab. The patient was a 48-year-old Japanese woman with advanced lung cancer who had been heavily pretreated using several lines of chemotherapy. Ramucirumab was administered as the fifth-line treatment with docetaxel. After 10 days, a painless rice-coloured or pink papule appeared on her finger. One month later, it increased in size to 20 mm. We examined the pathological condition by immunostaining using the resected specimen diagnosed as pyogenic granuloma. Paradoxically, this vascular tumour arose during the administration of an angiogenesis inhibitor.
format Online
Article
Text
id pubmed-6887457
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-68874572019-12-04 Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment Ibe, Tatsuya Hamamoto, Yoichiro Takabatake, Mikage Kamoshida, Shingo BMJ Case Rep Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect The angiogenesis inhibitor ramucirumab (IMC-1121B) is a fully humanised IgG1 monoclonal antibody targeting the extracellular domain of vascular endothelial growth factor receptor 2. Ramucirumab has been approved as a second-line treatment for lung cancer. Pyogenic granuloma is an acquired, benign vascular tumour of the skin or mucous membrane. We encountered a patient with pyogenic granuloma who was treated with ramucirumab. The patient was a 48-year-old Japanese woman with advanced lung cancer who had been heavily pretreated using several lines of chemotherapy. Ramucirumab was administered as the fifth-line treatment with docetaxel. After 10 days, a painless rice-coloured or pink papule appeared on her finger. One month later, it increased in size to 20 mm. We examined the pathological condition by immunostaining using the resected specimen diagnosed as pyogenic granuloma. Paradoxically, this vascular tumour arose during the administration of an angiogenesis inhibitor. BMJ Publishing Group 2019-11-26 /pmc/articles/PMC6887457/ /pubmed/31776151 http://dx.doi.org/10.1136/bcr-2019-231464 Text en © BMJ Publishing Group Limited 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
Ibe, Tatsuya
Hamamoto, Yoichiro
Takabatake, Mikage
Kamoshida, Shingo
Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment
title Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment
title_full Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment
title_fullStr Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment
title_full_unstemmed Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment
title_short Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment
title_sort development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment
topic Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887457/
https://www.ncbi.nlm.nih.gov/pubmed/31776151
http://dx.doi.org/10.1136/bcr-2019-231464
work_keys_str_mv AT ibetatsuya developmentofpyogenicgranulomawithstrongvascularendothelialgrowthfactorreceptor2expressionduringramucirumabtreatment
AT hamamotoyoichiro developmentofpyogenicgranulomawithstrongvascularendothelialgrowthfactorreceptor2expressionduringramucirumabtreatment
AT takabatakemikage developmentofpyogenicgranulomawithstrongvascularendothelialgrowthfactorreceptor2expressionduringramucirumabtreatment
AT kamoshidashingo developmentofpyogenicgranulomawithstrongvascularendothelialgrowthfactorreceptor2expressionduringramucirumabtreatment